AGIOS PHARMACEUTICALS, INC. (AGIO) Current Ratio
- Current ratio · latest quarter: Value 10.22×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 10.22× | Current assets / current liabilities. $717.67M ÷ $70.22M ≈ 10.22× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 717.67M USD | Assets, Current |
| Current obligations | 70.22M USD | Liabilities, Current |
| Cash and equivalents | 99.65M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 517.93M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory | 35.75M USD | Inventory, Net |
| Payables | 16.34M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $717.67M | $70.22M | $99.65M | $517.93M | (m) | $35.75M | $16.34M | (m) | 10.22× |
| 2026-03-31 | $834.84M | $58.84M | $113.60M | $623.44M | (m) | $35.09M | $13.75M | (m) | 14.19× |
| 2025-12-31 | $942.05M | $82.21M | $89.13M | $765.29M | (m) | $32.92M | $18.36M | (m) | 11.46× |
| 2025-09-30 | $1.03B | $74.76M | $92.71M | $860.15M | (m) | $32.03M | $19.55M | (m) | 13.82× |
| 2025-06-30 | $1.02B | $70.41M | $80.87M | $858.07M | (m) | $30.85M | $17.53M | (m) | 14.48× |
| 2025-03-31 | $968.62M | $52.37M | $78.96M | $814.41M | (m) | $29.61M | $13.73M | (m) | 18.50× |
| 2024-12-31 | $965.60M | $81.16M | $76.25M | $817.46M | (m) | $27.62M | $16.64M | (m) | 11.90× |
| 2024-09-30 | $1.07B | $119.45M | $253.73M | $751.03M | (m) | $26.43M | $17.14M | (m) | 8.99× |
| 2024-06-30 | $632.13M | $62.64M | $84.52M | $485.37M | (m) | $23.94M | $10.04M | (m) | 10.09× |
| 2024-03-31 | $663.63M | $51.69M | $118.76M | $479.23M | (m) | $23.07M | $11.15M | (m) | 12.84× |
| 2023-12-31 | $833.84M | $67.95M | $88.20M | $688.72M | (m) | $19.08M | $9.78M | (m) | 12.27× |
| 2023-09-30 | $704.35M | $58.42M | $64.33M | $583.15M | (m) | $17.27M | $13.27M | (m) | 12.06× |
| 2023-06-30 | $757.24M | $55.14M | $84.75M | $617.81M | (m) | $15.67M | $11.63M | (m) | 13.73× |
| 2023-03-31 | $791.66M | $45.11M | $104.14M | $635.06M | (m) | $11.37M | $8.66M | (m) | 17.55× |
| 2022-12-31 | $832.77M | $62.63M | $139.26M | $643.86M | (m) | $8.49M | $18.62M | (m) | 13.30× |
| 2022-09-30 | $784.93M | $53.60M | $122.45M | $605.23M | (m) | $5.18M | $10.41M | (m) | 14.65× |
| 2022-06-30 | $870.01M | $48.40M | $88.54M | $730.77M | (m) | $4.06M | $7.79M | (m) | 17.98× |
| 2022-03-31 | $975.14M | $45.79M | $80.03M | $843.50M | (m) | $2.48M | $11.55M | (m) | 21.30× |
| 2021-12-31 | $1.06B | $59.83M | $203.13M | $816.89M | (m) | $0.00 | $16.70M | (m) | 17.79× |
| 2021-09-30 | $1.31B | $57.90M | $400.22M | (m) | (m) | (m) | $10.31M | (m) | 22.55× |
| 2021-06-30 | $1.70B | $60.65M | $969.12M | (m) | (m) | (m) | $7.65M | (m) | 28.07× |
| 2021-03-31 | $2.36B | $96.50M | $1.89B | $447.58M | (m) | (m) | $51.22M | (m) | 24.40× |
| 2020-12-31 | $636.68M | $94.39M | $127.44M | $445.49M | (m) | (m) | $17.72M | (m) | 6.74× |
| 2020-09-30 | $669.09M | $69.77M | $104.86M | $500.68M | (m) | $11.37M | $12.85M | (m) | 9.59× |
| 2020-06-30 | $846.36M | $64.35M | $295.86M | $494.27M | (m) | $11.23M | $15.46M | (m) | 13.15× |
| 2020-03-31 | $587.27M | $69.86M | $89.09M | $439.53M | (m) | $9.78M | $18.71M | (m) | 8.41× |
| 2019-12-31 | $611.70M | $92.89M | $80.93M | $483.95M | (m) | $7.33M | $21.90M | (m) | 6.59× |
| 2019-09-30 | $490.14M | $92.43M | $81.71M | $370.19M | (m) | $5.85M | $21.51M | (m) | 5.30× |
| 2019-06-30 | $533.71M | $89.50M | $83.58M | $411.81M | (m) | $4.66M | $15.44M | (m) | 5.96× |
| 2019-03-31 | $557.10M | $80.91M | $103.44M | $421.11M | (m) | $2.33M | $12.41M | (m) | 6.89× |
| 2018-12-31 | $613.78M | $93.50M | (m) | (m) | (m) | (m) | (m) | (m) | 6.56× |
| 2018-09-30 | $695.54M | $84.75M | $156.48M | $513.41M | (m) | $863.00K | $16.62M | (m) | 8.21× |
| 2018-06-30 | $753.78M | $84.87M | $210.32M | $506.58M | (m) | (m) | $17.32M | (m) | 8.88× |
| 2018-03-31 | $802.99M | $74.70M | $364.47M | $417.98M | (m) | (m) | $17.93M | (m) | 10.75× |
| 2017-12-31 | $445.26M | $94.94M | $102.72M | $321.21M | (m) | $0.00 | $22.77M | (m) | 4.69× |
| 2017-09-30 | $528.31M | $88.11M | $132.74M | $375.19M | (m) | (m) | $17.90M | (m) | 6.00× |
| 2017-06-30 | $604.68M | $93.65M | $138.72M | $447.32M | (m) | (m) | $23.41M | (m) | 6.46× |
| 2017-03-31 | $506.87M | $82.43M | $200.28M | $279.48M | (m) | (m) | $16.15M | (m) | 6.15× |
| 2016-12-31 | $559.89M | $88.43M | $160.75M | $380.56M | (m) | (m) | $17.11M | (m) | 6.33× |
| 2016-09-30 | $600.94M | $78.00M | $285.50M | $293.60M | (m) | (m) | $15.42M | (m) | 7.70× |
| 2016-06-30 | $484.16M | $67.26M | $234.05M | $231.32M | (m) | (m) | $18.45M | (m) | 7.20× |
| 2016-03-31 | $329.47M | $45.05M | $39.03M | $273.86M | (m) | (m) | $13.75M | (m) | 7.31× |
| 2015-12-31 | $337.33M | $52.89M | $71.76M | $245.24M | (m) | (m) | $14.75M | (m) | 6.38× |
| 2015-09-30 | $371.66M | $49.76M | $80.05M | $272.32M | (m) | (m) | $8.97M | (m) | 7.47× |
| 2015-06-30 | $390.15M | $45.20M | $72.53M | $297.26M | (m) | (m) | $8.91M | (m) | 8.63× |
| 2015-03-31 | $364.14M | $36.38M | $35.26M | $309.45M | (m) | (m) | $12.64M | (m) | 10.01× |
| 2014-12-31 | $359.55M | $61.09M | $14.03M | $328.03M | (m) | (m) | $11.07M | (m) | 5.89× |
| 2014-09-30 | $247.56M | $35.08M | $70.05M | $149.92M | (m) | (m) | $6.22M | (m) | 7.06× |
| 2014-06-30 | $245.16M | $44.64M | $108.25M | $130.23M | (m) | (m) | $5.39M | (m) | 5.49× |
| 2014-03-31 | $172.42M | $34.08M | $32.84M | $129.43M | (m) | (m) | $4.41M | (m) | 5.06× |
| 2013-12-31 | $169.75M | $36.93M | $71.56M | $95.21M | (m) | (m) | $3.68M | (m) | 4.60× |
| 2013-09-30 | $198.82M | $37.38M | $106.01M | $88.94M | (m) | (m) | $2.14M | (m) | 5.32× |
| 2013-06-30 | $102.53M | $36.98M | $77.48M | $21.79M | (m) | (m) | $3.04M | (m) | 2.77× |
| 2012-12-31 | $130.14M | $35.11M | $91.30M | $36.68M | (m) | (m) | $3.31M | (m) | 3.71× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |